CryoPort Inc (DE:CKX)
FRANKFURT:CKX
CKX Stock Chart & Stats
€8.05
-€0.05(-0.61%)
At close: 4:00 PM EST
€8.05
-€0.05(-0.61%)
Day’s Range― - ―
52-Week Range€4.96 - €13.90
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€716.13M
Enterprise Value€748.39M
Total Cash (Recent Filing)€403.63M
Total Debt (Recent Filing)€230.49M
Price to Earnings (P/E)10.4
Beta1.01
Next Earnings
Aug 11, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.43
Shares Outstanding50,402,313
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.96
Price to Sales (P/S)2.73
P/FCF Ratio-17.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€12.97Price Target Upside61.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.67
Revenue Forecast (FY)€167.46M
Bulls Say, Bears Say
Bulls Say
Revenue Momentum & Upgraded GuidanceSustained double-digit top-line growth and a raised FY guide reflect durable demand for temperature-controlled logistics. Improved revenue visibility supports higher capacity utilization and provides a realistic runway for the company to convert operating leverage into sustained adjusted EBITDA improvement across the next 2–6 months.
Deep Clinical & Commercial FootprintA large pipeline of trials and meaningful Phase III exposure create a durable, growing addressable base that steadily converts to higher-frequency commercial shipments. This breadth reduces concentration risk and underpins recurring contracted revenue as therapies progress to commercialization over the medium term.
Product Diversification And New Product AdoptionGrowing product sales (MVE, Fusion 800) diversify revenue beyond per-shipment services, creating higher-margin, recurring consumables and validated hardware demand. Proprietary systems expand addressable markets and strengthen stickiness, improving margin sustainability as volumes scale into 2026–2027.
Bears Say
Weak Cash GenerationNegative operating and free cash flow indicate the business is not yet self-funding. Persistent cash burn constrains reinvestment, increases reliance on external capital for growth or capacity builds, and elevates execution risk during the multi-quarter path to positive adjusted EBITDA.
Operating Profitability Still NegativeCore operating losses despite positive net income imply earnings are supported by non-operating items. Until EBIT/EBITDA sustainably turn positive, earnings quality and margin durability remain questionable, limiting free cash flow conversion and long-term financial flexibility.
Long Onboarding And Delayed Facility RampExtended onboarding cycles for IntegraCell and slow ramp of new sites mean meaningful revenue and margin benefits are deferred into 2027. This timing mismatch creates risk that near-term investment and capacity increases won't produce immediate returns, delaying durable profitability.
CryoPort News
CKX FAQ
What was CryoPort Inc’s price range in the past 12 months?
CryoPort Inc lowest stock price was €4.96 and its highest was €13.90 in the past 12 months.
What is CryoPort Inc’s market cap?
CryoPort Inc’s market cap is €716.13M.
When is CryoPort Inc’s upcoming earnings report date?
CryoPort Inc’s upcoming earnings report date is Aug 11, 2026 which is in 67 days.
How were CryoPort Inc’s earnings last quarter?
CryoPort Inc released its earnings results on May 04, 2026. The company reported -€0.215 earnings per share for the quarter, missing the consensus estimate of -€0.186 by -€0.029.
Is CryoPort Inc overvalued?
According to Wall Street analysts CryoPort Inc’s price is currently Undervalued.
Does CryoPort Inc pay dividends?
CryoPort Inc does not currently pay dividends.
What is CryoPort Inc’s EPS estimate?
CryoPort Inc’s EPS estimate is -0.17.
How many shares outstanding does CryoPort Inc have?
CryoPort Inc has 50,402,313 shares outstanding.
What happened to CryoPort Inc’s price movement after its last earnings report?
CryoPort Inc reported an EPS of -€0.215 in its last earnings report, missing expectations of -€0.186. Following the earnings report the stock price went up 5.814%.
Which hedge fund is a major shareholder of CryoPort Inc?
Currently, no hedge funds are holding shares in DE:CKX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CryoPort Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€12.97 (61.18% Upside)
€12.97 (61.18% Upside)
Insider Transactions
Sold Shares
Worth €107.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.93%
12-Months-Change
Fundamentals
Return on Equity
16.16%
Trailing 12-Months
Asset Growth
9.11%
Trailing 12-Months
Company Description
CryoPort Inc
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
CKX Company Deck
CKX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive operational and financial picture: strong 16% revenue growth, double-digit expansion across services and products, record clinical trial support, product innovation (Fusion 800), and a $2.2M improvement in adjusted EBITDA. Management raised full-year revenue guidance and expects positive adjusted EBITDA in H2 2026. Key near-term cautions include a conservative guide raise despite a beat, the company not yet at positive adjusted EBITDA, product-margin mix variability, and multi-quarter ramps for IntegraCell and new facilities that limit 2026 contribution. Overall the positives (top-line growth, pipeline depth, milestones, margin improvement initiatives, and operational expansions) materially outweigh the identified lowlights.View all DE:CKX earnings summariesCKX Stock 12 Month Forecast
Average Price Target
€12.97
▲(61.18% Upside)
Technical Analysis
Options Prices
Currently, No data available
---